Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis

Abstract

Erythrodermic psoriasis (EP) and generalized pustular psoriasis (GPP) are the most severe forms of psoriasis, resulting in significant morbidity and even mortality ¹. There are few evidence-based data on their treatment ^2,3. Secukinumab, a fully human anti-IL-17A monoclonal antibody, demonstrated strong efficacy in treating moderate to severe plaque-type psoriasis ^4,5.

This article is protected by copyright. All rights reserved.

http://ift.tt/2nei7pl